Journal Home
Search for

Volume 72, Issue 2, Pages 247-254 (August 2008)


View previous. 8 of 78 View next.

Prostate Tissue Androgens: History and Current Clinical Relevance

Leonard S. MarksabCorresponding Author Informationemail address, Elahe A. Mostaghelc, Peter S. Nelsonc

Received 24 January 2008; accepted 25 March 2008. published online 27 May 2008.

Direct determination of androgen levels in prostate tissue provides a perspective on the organ that is not available via androgen serum levels. The principle prostatic androgens, primarily dihydrotestosterone (DHT) and secondarily testosterone, can be readily assayed in quick-frozen prostate biopsy cores or surgical specimens. Such assays have proved important in establishing (1) that DHT is a permissive factor in BPH pathogenesis, (2) a mechanism for the treatment of BPH, (3) an understanding of prostate cancer chemoprevention, (4) an explanation for the ‘escape’ of prostate cancer from castration therapy, (5) prostate safety of testosterone replacement therapy, and (6) insights into the cause of racial differences of prostate cancer. Future opportunities include clarification of new drug mechanisms for BPH and prostate cancer, as well as a better understanding of the pathogenesis of both, and as an aid in individual patient management. Determination of prostate tissue androgens may soon transition from research tool to clinical test.

a Department of Urology, University of California, Los Angeles, Geffen School of Medicine, Los Angeles, California

b Urological Sciences Research Foundation, Culver City, California

c Divisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington

Corresponding Author InformationReprint requests: Leonard S. Marks, M.D., Urological Sciences Research Foundation, Culver Medical Plaza, 3831 Hughes Avenue, Suite 501, Culver City, CA 90232.

 This work was supported by the Urological Sciences Research Foundation (L.S.M.); a Career Development Award from the Prostate Cancer Foundation, a Young Investigator Award from the American Society of Clinical Oncology, and National Institutes of Health grant K23 CA122820-02 (E.A.M.); and the National Institutes of Health/National Cancer Institute Pacific Northwest Prostate Cancer SPORE grant P50CA97186 (P.S.N.).

PII: S0090-4295(08)00372-5

doi:10.1016/j.urology.2008.03.033


View previous. 8 of 78 View next.